Though an important cause of morbidity and mortality in solid organ transplantation (SOT),
the long-term outcomes of cytomegalovirus (CMV) disease treatment have not been well …

We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in
preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant …

Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ
transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized …

Valganciclovir (VGC) has proved efficacious and safe for the prophylaxis against
cytomegalovirus (CMV) in high-risk transplant recipients and for the treatment of CMV …

Despite remarkable advances in the diagnostic and therapeutic modalities for its
management, cytomegalovirus (CMV) remains one of the most important pathogens …

We assessed valganciclovir for the treatment of cytomegalovirus (CMV) in organ-transplant
recipients. Virologic and clinical outcomes were compared with those in matched historical …

The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and
disease progression. The clinical significance of such resistance in solid-organ …

Background: Although the primary treatment of symptomatic cytomegalovirus (CMV) disease
in organ transplant recipients is successful in> 90% of individuals, relapsing disease …

The clinical and virologic efficacy of ganciclovir (9-[1, 3-dihydroxy-2-propoxymethyl]
guanine) in the treatment of severe CMV infections in solid organ transplant recipients was …

The occurrence of cytomegalovirus infection after solid organ transplantation has been
correlated with decreased patient and allograft survival. The disease has not been …